faq Vaginal Laxity (postnatalmenopause support)

Can HA fillers improve cushioning but not “tighten” the vagina?

Yes—superficial hyaluronic-acid (HA) injectables can add hydration and a gentle cushion at the entrance (vestibule) and lower vaginal wall, easing friction, sting and micro-tears. They do not surgically “tighten” deeper support tissues, correct prolapse or replace pelvic floor training. Think of them as a comfort layer alongside foundations: moisturiser/lubricant, local oestrogen (if acceptable), and supervised pelvic floor rehab. Educational only. Results vary. Not a cure.

Clinical Context

Likely to benefit. Postnatal or peri-/post-menopausal women with focal vestibular sting, recurrent “paper-cut” splits, or early-penetration soreness despite good lubrication—especially where GSM is present and pelvic floor endurance is reasonable. HA may provide a gentle cushion that reduces friction so training and intimacy are easier.

Less suitable right now. Pregnancy; active infection; fever or foul discharge; new post-menopausal bleeding; recent pelvic/perineal surgery without clearance; suspected prolapse beyond the introitus; pain-dominant/overactive pelvic floor (needs down-training and psychosexual support first); clear scar malposition (consider scar-aware therapy and, occasionally, surgical opinion).

Next steps. Continue a supervised 12-week pelvic floor block; schedule a vaginal moisturiser 2–4 nights weekly; use a generous, compatible lubricant (water-based for versatility/condoms; silicone-based for longest glide; avoid oil with latex); note wins (fewer micro-tears, easier speculum/tampon use) to decide if HA is worth adding.

Evidence-Based Approaches

NHS, patient-friendly foundations: Practical guidance on pelvic floor training and vaginal dryness self-care: NHS pelvic floor exercises; NHS – vaginal dryness.

NICE menopause guideline (NG23): Recommends vaginal moisturisers/lubricants and considering low-dose local vaginal oestrogen when symptoms affect quality of life; procedural/injectable options are not first-line for GSM or “laxity”. NICE NG23.

NICE urinary incontinence/prolapse (NG123): Emphasises supervised pelvic floor muscle training as first-line with clear criteria for escalation—principles that underpin stepwise decisions before any adjunct. NICE NG123.

Cochrane reviews: Systematic reviews consistently support pelvic floor muscle training for continence/pelvic floor symptoms—hence foundations before injectables or devices. Cochrane Library – PFMT reviews.

Regulatory perspective (UK): Selection should consider product intended use and appropriate UKCA/CE marking; unexpected effects can be reported via national schemes. MHRA – medical devices.